

NEWS RELEASE

BIOSENSORS ANNOUNCES APPOINTMENT OF DR. JACK WANG AS CHIEF OPERATING OFFICER

Singapore, 21 July 2008 – Biosensors International Group, Ltd. (“Biosensors”, “Company”, Bloomberg: BIG SP), announced the appointment of Dr. Jack Wang as Chief Operating Officer, effective today. Dr. Wang has been involved in Biosensors’ operating activities and product development efforts since 2001, most recently serving as the Chief Executive Officer of JW Medical Systems (“JWMS”), the Company’s China-based joint venture with Shandong Weigao Group Medical Polymer Company Limited. Under his leadership, JWMS became one of the top three providers of drug-eluting stents in China within two years of the launch its Excel drug-eluting stent. Dr. Wang will remain as the senior officer of JWMS and will assume responsibility for all operating activities of Biosensors, including manufacturing, quality and product development.

“Jack has been one of Biosensors’ most important resources for many years,” commented Mike Kleine, President and Chief Executive Officer of Biosensors. Kleine continued, “Under Jack’s direction, JWMS has become a major factor in the China stent market, as he has been the driving force of that operation since its inception. As we now prepare for accelerated business growth, we need someone of Jack’s capabilities to lead our operations. We also expect that Jack’s product development experience and vision will greatly accelerate the commercialization of our new product pipeline.”

Dr. Wang said, “I am very excited at the prospect of increased responsibility at Biosensors. While I will continue to function as CEO of JWMS, we have laid a strong foundation at JWMS over the past several years and I am confident that our China team is capable of continued growth, as I shift a significant portion of my time to Biosensors global operating activities. We also have a great operating team at Biosensors and I look forward to the challenges of the BioMatrix launch.”

Prior to joining Biosensors in 2001, Dr. Wang served as Manager in new product development for Johnson & Johnson (Cordis) and as Project Group Leader in stent delivery systems for Guidant Corporation. Dr. Wang has been granted more than 20 US and European patents in medical devices and technology and has published more than 30 scientific papers on polymer materials and processing.

Dr. Wang received his doctorate in polymer science from Case Western Reserve University, Cleveland, Masters Degree from Clarkson University, Potsdam and Bachelor of Science degree in Chemistry and Chemical Engineering from Tsinghua University, Beijing.

END OF RELEASE

Media Relations & Investor Relations
Biosensors International Group
Mr. Loh Chee Mun
Senior Vice President
Tel: (65) 6213 5708
Email: cm.loh@biosensors.com

Media Relations / Investor Relations Firm
United States
Allen & Caron Inc.
Mr. Matt Clawson
Executive Vice President, Investor Relations
Tel: (1) 949 474 4300
Email: matt@allencaron.com

About Biosensors International Group, Ltd

Biosensors develops, manufactures and markets innovative medical devices used in interventional cardiology and critical care procedures. Biosensors is well-positioned to emerge as a leader in drug-eluting stents and has developed a pipeline of next-generation products that are set to gain market share from traditional therapies such as conventional drug-eluting stents, bare-metal stenting and open-heart surgery. It has three separate drug-eluting stent programs, BioMatrix®, Axxion™, and BioFreedom™, a completely polymer-free drug-eluting stent.

For more information, please visit www.biosensors.com.

About BioMatrix®

BioMatrix® offers the unique combination of an innovative anti-restenotic drug, Biolimus A9®, a biodegradable poly-lactic acid polymer (PLA), and an advanced, highly flexible stent designed for enhanced deliverability.

Biolimus A9 was designed specifically for use in drug-eluting stent systems. In addition to effective immunosuppressive and anti-inflammatory properties, the drug has a higher lipophilic and hydrophobic profile than other limus analogs, enabling rapid absorption of the drug into the targeted tissue and reduced systemic exposure. Precision automated coating ensures the PLA and drug combination is applied only to the abluminal (outer) surface of the stent. The PLA fully degrades into water and carbon dioxide as the drug elutes, ultimately leaving in place a biocompatible stent surface.

For more information, please visit www.biomatrix.com

Forward-Looking Statements

Certain statements herein include forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements generally can be identified by the use of forward-looking terminology, such as “may,” “will,” “expect,” “intend,” “estimate,” “anticipate,” “believe,” “project” or “continue” or the negative thereof or other similar words. All forward looking statements involve risks and uncertainties, including, but not limited to, customer acceptance and market share gains, competition from companies that have greater financial resources; introduction of new products into the marketplace by competitors; successful product development; dependence on significant customers; the ability to recruit and retain quality employees as Biosensors grows; and economic and political conditions globally. Actual results may differ materially from those discussed in, or implied by, the forward-looking statements. The forward-looking statements speak only as of the date of this release and Biosensors assumes no duty to update them to reflect new, changing or unanticipated events or circumstances.